Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

Abstract # 443: oral presentation

Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase

Inhibitor in Elderly and/or Treatment Refractory Patients with Acute

Myeloid Leukemia

Location and timing: Acute Myeloid Leukemias: Therapy, excluding

Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,

2007, 13:30-15:00 Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

Abstract # 1608, Poster # 762

Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of

AML by the Novel Agent CHR-2797

Location and timing: Poster Session I, Hall B4: Saturday, December 8,

2007, 17:30-19:30 Eastern Standard Time

Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)

Abstract # 2505, Poster # 695

Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in


Location and timing: Poster Session II, Hall B4: Sunday, December 9,

2007, 18:00-20:00, Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

The ASH posters will be available at the company's website, following the above presentations.


Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer


Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at

SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... Effective immediately, ... In addition starting on Black Friday Target is offering a “Buy One Scrub ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
Breaking Medicine Technology: